Abstract
In the last few years, major advances in the treatment of transplant recipients, with hemato-oncological diseases or admitted to the intensive care unit, has been accompanied by an increase in classical fungal infections and by the emergence of uncommon fungal infections. Despite the development of new diagnostic techniques such as galactomannan detection and the availability of new antifungal agents, these opportunistic infections continue to pose a diagnostic challenge, prolong length of hospital stay, and increase costs. In addition, mortality from these infections is high. The present chapter provides a brief review of the epidemiology of these infections, diagnostic advances, and the new antifungal agents that have been developed in the last few years.
MeSH terms
-
Anidulafungin
-
Antifungal Agents / therapeutic use*
-
Aspergillosis / diagnosis
-
Aspergillosis / drug therapy
-
Aspergillosis / etiology
-
Candidiasis / diagnosis
-
Candidiasis / drug therapy
-
Candidiasis / etiology
-
Clinical Trials as Topic
-
Critical Care
-
Diabetes Complications / microbiology
-
Disease Susceptibility
-
Echinocandins / therapeutic use
-
Fungemia / diagnosis
-
Fungemia / drug therapy*
-
Fungemia / etiology
-
Fungemia / microbiology
-
Galactose / analogs & derivatives
-
Hematologic Diseases / complications
-
Hematologic Diseases / drug therapy
-
Humans
-
Immunocompromised Host
-
Mannans / blood
-
Meta-Analysis as Topic
-
Mycoses / diagnosis
-
Mycoses / drug therapy*
-
Mycoses / etiology
-
Mycoses / microbiology
-
Neoplasms / complications
-
Neoplasms / drug therapy
-
Opportunistic Infections / diagnosis
-
Opportunistic Infections / drug therapy*
-
Opportunistic Infections / etiology
-
Opportunistic Infections / microbiology
-
beta-Glucans / blood
Substances
-
Antifungal Agents
-
Echinocandins
-
Mannans
-
beta-Glucans
-
galactomannan
-
beta-1,3-glucan
-
Anidulafungin
-
Galactose